-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
1 view
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about PepGen's business, operations, and prospects, including allegations that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; and (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated.
